ARS Pharmaceuticals(SPRY) - 2022 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR (Exact name of Registrant as specified in its Charter) Delaware 81-1489190 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 500 Fairview Ave N, Suite 600 Seattle, Washington 98109 (Address of principal executive offices) (Zip ...